No Data
H.C. Wainwright Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $25
H.C. Wainwright analyst Douglas Tsao maintains $Sage Therapeutics(SAGE.US)$ with a hold rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 37.8
SAGE Therapeutics: A Balanced Hold Rating Amidst Promising Zurzuvae Launch and Clinical Pipeline Prospects
Needham Reiterates Hold on Sage Therapeutics
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
19 Analysts Have This To Say About Sage Therapeutics
Across the recent three months, 19 analysts have shared their insights on Sage Therapeutics (NASDAQ:SAGE), expressing a variety of opinions spanning from bullish to bearish.The following table provide
J.P. Morgan Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Cuts Target Price to $23
J.P. Morgan analyst Anupam Rama maintains $Sage Therapeutics(SAGE.US)$ with a buy rating, and adjusts the target price from $28 to $23.According to TipRanks data, the analyst has a success rate of 43.